

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Approval Package for:**

***APPLICATION NUMBER:***

**20-564 / S-017**

***Trade Name:*** Epivir

***Generic Name:*** (Lamivudine)

***Sponsor:*** GlaxoSmithKline

***Approval Date:*** September 13, 2002

# CENTER FOR DRUG EVALUATION AND RESEARCH

***APPLICATION NUMBER:***

**20-564 / S-017**

## CONTENTS

### **Reviews / Information Included in this NDA Review.**

<b>Approval Letter</b>	<b>X</b>
<b>Approvable Letter</b>	
<b>Labeling</b>	
<b>Medical Review(s)</b>	
<b>Chemistry Review(s)</b>	<b>X</b>
<b>EA/FONSI</b>	
<b>Pharmacology Review(s)</b>	
<b>Statistical Review(s)</b>	
<b>Microbiology Review(s)</b>	
<b>Clinical Pharmacology/ Biopharmaceutics Review(s)</b>	
<b>Administrative and Correspondence Document(s)</b>	

**CENTER FOR DRUG EVALUATION AND RESEARCH**

***APPLICATION NUMBER:***

**20-564 / S-017**

**APPROVAL LETTER**



NDA 20-564/S-017  
NDA 20-596/S-018  
NDA 20-857/S-011  
NDA 21-003/S-003  
NDA 21-004/S-003

GlaxoSmithKline  
Attention: Kevin A. Miller, R.Ph., RAC  
Assistant Director, CMC Regulatory Affairs  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709

Dear Mr. Miller:

Please refer to your supplemental new drug applications dated March 20, 2002, received March 21, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for:

EPIVIR<sup>®</sup> (lamivudine) Tablets, 150 mg and 300 mg,  
EPIVIR<sup>®</sup> (lamivudine) Oral Solution, 10 mg/mL,  
COMBIVIR<sup>®</sup> (lamivudine and zidovudine) Tablets, 150 mg of lamivudine, and 300 mg  
of zidovudine per tablet,  
EPIVIR-HBV<sup>®</sup> (lamivudine) Tablets, 100 mg, and  
EPIVIR-HBV<sup>®</sup> (lamivudine) Oral Solution, 5 mg/mL.

These "Changes Being Effected in 30 days" supplemental new drug applications provide for approval of Glaxo Wellcome Manufacturing, \_\_\_\_\_ as an alternate manufacturing site for \_\_\_\_\_

\_\_\_\_\_. This site will also be used for quality control testing for the \_\_\_\_\_ and for quality control and stability testing for lamivudine drug substance.

These submissions also include alternate analytical methods for \_\_\_\_\_ for \_\_\_\_\_

We have completed the review of these supplemental applications, and they are approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

---

Food and Drug Administration  
Rockville MD 20857

If you have any questions, call Christine Lincoln, RN, MS, MBA, Regulatory Project Manager, at (301) 827-2335.

Sincerely,

*{See appended electronic signature page}*


Stephen P. Miller, Ph.D.  
Chemistry Team Leader for the  
Division of Antiviral Drug Products, (HFD-530)  
DNDC III, Office of New Drug Chemistry  
Center for Drug Evaluation and Research

**CENTER FOR DRUG EVALUATION AND RESEARCH**

*APPLICATION NUMBER:*

**20-564 / S-017**

**CHEMISTRY REVIEW(S)**

<b>SUPPLEMENTAL NDA CHEMIST'S REVIEW</b>		<b>DUE DATE</b> 9/21/02	<b>1. ORGANIZATION</b> HFD-530	<b>2. NDA NUMBER</b> 20-564					
<b>3. NAME AND ADDRESS OF APPLICANT</b> Glaxo Wellcome Inc. Five Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709 Attn: Kevin A. Miller			<b>4. TYPE OF SUPPLEMENT</b> CBE-30						
			<b>5. DOCUMENT(S)</b>						
			<b>NUMBERS</b> SCM-017	<b>DATED</b> 3/20/02	<b>RECEIVED</b> 3/21/02				
<b>6. NAME OF DRUG</b> EPIVIR® Tablets			<b>7. NONPROPRIETARY NAME</b> lamivudine tablets						
<b>8. SUPPLEMENT PROVIDES FOR:</b> An alternate manufacturing, quality control testing, and stability testing site at _____				<b>9. AMENDMENTS/DATES</b>					
<b>10. PHARMACOLOGICAL CATEGORY</b> Anti-HIV		<b>11. HOW DISPENSED</b> <input checked="" type="checkbox"/> R <input type="checkbox"/> OTC		<b>12. RELATED IND/NDA/DMF(s)</b>					
<b>13. DOSAGE FORM(S)</b> Tablets			<b>14. POTENCY (CIES)</b> 150 mg						
<b>15. CHEMICAL NAME AND STRUCTURE</b> (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one			<b>16. MEMORANDA</b>						
									
<b>17. COMMENTS</b>									
<p>on 4/12/02. On 8/21/02 an overall recommendation of "Acceptable" was made.</p>									
<b>18. CONCLUSIONS AND RECOMMENDATIONS</b> This Supplement is therefore recommended for approval.									
<b>19. REVIEWER</b>									
<b>NAME</b> George Lunn, Ph.D.		<b>SIGNATURE</b> [signed electronically in DFS]		<b>DATE OF DRAFT REVIEW</b> 27-Aug-2002					
<b>20. CONCURRENCE:</b> HFD-530/SMiller [signed electronically in DFS]									
<b>DFS CC LIST</b>	<input type="checkbox"/>	L	GLunn	<input type="checkbox"/>	L	Med: BStyrt	<input type="checkbox"/>	<input type="checkbox"/>	PharmTox
L = Action Letter	<input type="checkbox"/>	R	L	SMiller	<input type="checkbox"/>	R	L	PM: CLincoln	Micro
R = Review	<input type="checkbox"/>	R	L	CChen	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Biopharm	

**WITHHOLD 6 PAGE(S)**

B<sub>4</sub>

Chemistry Review